CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are a safe and effective preventive treatment for episodic migraine. This is the conclusion of a meta-analysis of four randomised controlled trials including 1198 patients, identified by a systematic database search of studies published up to 2 April 2016. The pooled estimate showed that, when compared with placebo, …
Read more »The latest report from the Global Burden of Disease Study, GBD 2015, shows that world-wide, migraine is in the top 10 causes of years lived with disability (YLDs), especially among those aged 45-64 years. Migraine also ranked within the top 6 causes of YLDs among younger individuals, including adolescents (aged 15 years or more). The …
Read more »People with migraine have a higher incidence of cardiovascular disease, most notably, stroke. A contributing factor may be an increased propensity for the development of the metabolic syndrome, defined as a clustering of cardiovascular risk factors, specifically hypertension, insulin resistance, dyslipidaemia and central adiposity. The current study adds further evidence for this association, specifically in …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
